BSE Live
Apr 20, 16:01Prev. Close
654.40
Open Price
656.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 20, 15:58Prev. Close
655.70
Open Price
657.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
664.45 (1185)
| Cash Flow of Granules India (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 660.17 | 547.23 | 687.17 | 558.00 | 704.36 | |
| Net CashFlow From Operating Activities | 866.57 | 439.41 | 738.75 | 332.05 | 432.48 | |
| Net Cash Used In Investing Activities | -691.29 | -360.16 | -191.36 | -380.11 | -277.14 | |
| Net Cash Used From Financing Activities | -92.51 | 7.66 | -440.29 | 190.00 | -299.31 | |
| Foreign Exchange Gains / Losses | 2.24 | 2.63 | -0.25 | 0.94 | -0.12 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 85.01 | 89.54 | 106.84 | 142.88 | -144.09 | |
| Cash And Cash Equivalents Begin of Year | 381.10 | 291.56 | 184.71 | 41.84 | 185.93 | |
| Cash And Cash Equivalents End Of Year | 466.11 | 381.10 | 291.56 | 184.71 | 41.84 |
01.04.2026
Buy Granules India; target of Rs 800: Emkay Global Financial
01.04.2026
Granules India shares up 2% after arm gets VAI status post USFDA inspection
01.04.2026
30.03.2026
27.01.2026
Granules India Consolidated December 2025 Net Sales at Rs 1,387.94 crore, up 22% Y-o-Y
27.01.2026
Granules India Standalone December 2025 Net Sales at Rs 895.32 crore, up 6.31% Y-o-Y
26.11.2025
Granules India Consolidated September 2025 Net Sales at Rs 1,296.99 crore, up 34.18% Y-o-Y
24.11.2025
Granules India Standalone September 2025 Net Sales at Rs 891.61 crore, up 56.98% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth